SCHEMBL18520145

SCHEMBL18520145

CSCCCN1CCCC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.52
ALDH1A1 P00352 2/20 0.42
TSHR P16473 1/20 0.42
MAPT P10636 1/20 0.41
CARM1 Q86X55 1/20 0.41
PRMT6 Q96LA8 1/20 0.41
PRMT8 Q9NR22 1/20 0.41
CYP1A2 P05177 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
HRH1 P35367 1/20 0.37
KDM4E B2RXH2 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CXCR4 P61073 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17209067 0.98 HRH3 (0.56) HRH3ALDH1A1TSHRMAPTCARM1
SCHEMBL24132144 0.95
SCHEMBL24160080 0.89 HRH3 (0.65) HRH3ALDH1A1TSHRMAPTCYP1A2
SCHEMBL10061913 0.84
SCHEMBL17345965 0.83 SCN5A (0.43) HRH3ALDH1A1TSHRMAPTCARM1
SCHEMBL9881134 0.83 PAOX (0.44) HRH3ALDH1A1MAPTDRD3
SCHEMBL25544507 0.82 ALDH1A1 (0.48) HRH3ALDH1A1TSHRMAPTCARM1
SCHEMBL7238745 0.82 ALDH1A1 (0.48) HRH3ALDH1A1TSHRMAPTCARM1
SCHEMBL17346215 0.82 SIGMAR1 (0.46) HRH3
SCHEMBL21782724 0.81 KDM4E (0.41) ALDH1A1MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
US-10662177-B2 Blocking toll-like receptor 9 signaling with small molecule antagonist COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-05-26 US disclosed
US-20190092758-A1 BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2019-03-28 US disclosed
EP-3219207-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES The Trustees Of The University Of Pennsylvania (US) 2017-09-20 EP disclosed
US-20170253601-A1 Substituted Pyrrolidine Compounds Epizyme, Inc. (US) 2017-09-07 US disclosed
EP-2646043-B1 NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION S&T GLOBAL INC (US) 2017-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190092758-A1 BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST TLR9, TLR1, TLR3 HRH3 50/4885ALDH1A1 4590/4885TSHR 1209/4885
US-10662177-B2 Blocking toll-like receptor 9 signaling with small molecule antagonist TLR9, TLR1, TLR3 HRH3 79/4885ALDH1A1 4498/4885TSHR 1096/4885
US-20230399297-A1 Novel Glutamine Analogs GLUL, GATD3, GLS HRH3 2060/4885ALDH1A1 4320/4885TSHR 3476/4885
US-20170253601-A1 Substituted Pyrrolidine Compounds SMYD2, SMYD3, SNRPD2 HRH3 1731/4885ALDH1A1 1716/4885TSHR 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.